1.46
price down icon5.81%   -0.09
after-market Dopo l'orario di chiusura: 1.43 -0.03 -2.05%
loading
Precedente Chiudi:
$1.55
Aprire:
$1.5
Volume 24 ore:
2.90M
Relative Volume:
0.56
Capitalizzazione di mercato:
$316.12M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.6887
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
-13.10%
1M Prestazione:
-25.13%
6M Prestazione:
-47.86%
1 anno Prestazione:
-67.34%
Intervallo 1D:
Value
$1.39
$1.5019
Intervallo di 1 settimana:
Value
$1.39
$1.70
Portata 52W:
Value
$1.32
$4.45

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
Nome
Allogene Therapeutics Inc
Name
Telefono
(650) 457-2700
Name
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Dipendente
361
Name
Cinguettio
@AllogeneTx
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
ALLO's Discussions on Twitter

Confronta ALLO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.46 316.12M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-14 Aggiornamento Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 Ripresa Oppenheimer Outperform
2024-05-31 Iniziato Piper Sandler Overweight
2024-01-05 Downgrade Guggenheim Buy → Neutral
2024-01-05 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 Iniziato Citigroup Buy
2023-06-26 Ripresa Oppenheimer Outperform
2023-03-21 Iniziato Bernstein Mkt Perform
2023-01-24 Aggiornamento JP Morgan Neutral → Overweight
2023-01-06 Aggiornamento Robert W. Baird Neutral → Outperform
2022-12-12 Downgrade BofA Securities Buy → Underperform
2022-08-10 Downgrade Raymond James Outperform → Mkt Perform
2022-07-15 Aggiornamento Goldman Neutral → Buy
2022-06-03 Iniziato Robert W. Baird Neutral
2022-02-28 Reiterato B. Riley Securities Buy
2021-10-20 Iniziato Cowen Outperform
2021-10-08 Downgrade Goldman Buy → Neutral
2021-10-08 Downgrade Stifel Buy → Hold
2021-09-23 Aggiornamento Raymond James Mkt Perform → Outperform
2021-06-21 Ripresa Jefferies Buy
2021-05-20 Aggiornamento Truist Hold → Buy
2021-05-14 Iniziato B. Riley Securities Buy
2021-01-26 Aggiornamento Stifel Hold → Buy
2020-12-10 Ripresa H.C. Wainwright Buy
2020-11-24 Iniziato BofA Securities Buy
2020-10-23 Iniziato RBC Capital Mkts Outperform
2020-06-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-29 Reiterato H.C. Wainwright Buy
2020-05-19 Aggiornamento ROTH Capital Neutral → Buy
2020-05-15 Aggiornamento Guggenheim Neutral → Buy
2020-05-14 Reiterato H.C. Wainwright Buy
2020-05-14 Downgrade SunTrust Buy → Hold
2020-04-13 Iniziato SunTrust Buy
2020-03-13 Iniziato H.C. Wainwright Buy
2020-03-05 Iniziato Stifel Hold
2020-02-24 Iniziato Berenberg Hold
2019-12-18 Iniziato JMP Securities Mkt Outperform
2019-11-04 Iniziato Canaccord Genuity Buy
2019-08-09 Iniziato BTIG Research Buy
2019-06-05 Iniziato ROTH Capital Neutral
2019-05-31 Iniziato Guggenheim Neutral
2019-05-23 Iniziato Stifel Hold
2019-03-29 Iniziato Piper Jaffray Overweight
Mostra tutto

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics CEO sells $91,469 in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com

Mar 18, 2025
pulisher
Mar 17, 2025

7th Annual Allogeneic Cell Therapies Summit - pharmaphorum

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025
pulisher
Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlight - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene stock upgraded at Citizens post Q4 (ALLO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics: Q4 Earnings Snapshot - The Wilton Bulletin

Mar 14, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc Q4 Loss Per Share $0.28 -March 13, 2025 at 05:32 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Estimates; Revenue Falls Short - GuruFocus.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

ALLOGENE THERAPEUTICS Earnings Results: $ALLO Reports Quarterly Earnings - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics: Q4 Earnings Snapshot -March 13, 2025 at 05:05 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 08, 2025

Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire

Mar 05, 2025
pulisher
Mar 03, 2025

Foresight Diagnostics expands Allogene partnership - BizWest

Mar 03, 2025
pulisher
Mar 03, 2025

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

When Will Allogene Reveal Its CAR T Progress? Key Earnings Date Set - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Allogene Therapeutics Schedules Conference Call and Webcast for Q4 and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq

Mar 03, 2025
pulisher
Feb 27, 2025

Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia - The Malaysian Reserve

Feb 27, 2025
pulisher
Feb 27, 2025

Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities (NASDAQ:ALLO) - Seeking Alpha

Feb 26, 2025
pulisher
Feb 26, 2025

Allogene Expands Partnership With Foresight Diagnostics To Advance Cema-Cel Development Globally - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Allogene Therapeutics Announces Participation in March Investor Conference - The Manila Times

Feb 26, 2025

Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):